Bruscaggin, A., et al., Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
Balasubramanian, S., et al., Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib, British Journal of Haematology, https://doi.org/10.1111/bjh.17450
Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021
Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.
Gaudio, E., et al. Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identificaton of Potential Biomarkers for Its Activity. Blood Journal 2020 NOV 6. 136 (S1);17
Lodhi, N., et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 2020(11):44, 4055-4073.
Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).
Eyre, T. A., et al. A phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 Inhibitor Vistusertib in Relapsed, Refractory DLBCL. Hematological Oncology 2019; 37:352-359.
Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland. Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629
Page last updated October 27, 2022